Safety and Efficacy of MP-214 in Patients With Schizophrenia

NCT01625000 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

512

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: MP-214 3mg
DRUG: MP-214 6mg
DRUG: MP-214 9mg
DRUG: Risperidone 4mg
DRUG: Placebo

Sponsor

Tanabe Pharma Corporation